TY - JOUR AU - Fabris, M. AU - Quartuccio, L. AU - Lombardi, S. AU - Benucci, M. AU - Manfredi, M. AU - Saracco, M. AU - Atzeni, F. AU - Morassi, P. AU - Cimmino, M.A. AU - Pontarini, E. AU - Fabro, C. AU - Pellerito, R. AU - Sarzi-Puttini, P. AU - Cutolo, M. AU - Carletto, A. AU - Bambara, L.M. AU - Fischetti, F. AU - Curcio, F. AU - Tonutti, E. AU - De VIta, S. PY - 2010/12/30 Y2 - 2024/03/29 TI - Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis JF - Reumatismo JA - Reumatismo VL - 62 IS - 4 SE - Articles DO - 10.4081/reumatismo.2010.253 UR - https://www.reumatismo.org/reuma/article/view/reumatismo.2010.253 SP - 253-258 AB - Several studies demonstrated the efficacy of the B-cell depletion therapy with rituximab (RTX) in RA patients, including those unresponsive to anti- TNF therapy, underlying the important role of B cells in this disease (1-5). Several recent papers have demonstrated a differential effects of RTX in depleting B-cells and blocking plasma cell generation at the synovial and at the bone marrow level (7-9). This differential effect may explain why among patients who respond to RTX, some relapse while others show a very prolonged response, independently from the reappearance of B-cells in the peripheral blood (6). However, the efficacy of RTX may also depend on the individual genetic predisposition. At this regard, very few data were produced by now. ER -